Pioglitazone · Actos

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (1)
EU
  • Pioglitazone is indicated in the treatment of type-2 diabetes mellitus: as monotherapy: in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance; as dual oral therapy in combination with: metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin; a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic...
Product first approved 2000EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (64)
Type 2 Diabetes
NCT06246799 · The University of Texas Health Science Center at San Antonio
2024-11-07 – 2029-06-30 · Type 2 Diabetes (Adult Onset)
What this study did
NCT04271189 · Azienda Ospedaliero-Universitaria di Parma
2020-09-01 – 2024-12-31 · Newly Diagnosed Type 2 Diabetes
What this study did
NCT06107153 · University of Basrah
2023-11-01 – 2024-11-01 · Type2diabetes
What this study did
NCT05629806 · Nanjing First Hospital, Nanjing Medical University
2022-04-10 – 2023-05-31 · Type 2 Diabetes, Blood Glucose Fluctuation
What this study did
NCT05098327 · State University of New York at Buffalo
2021-08-01 – 2023-03-31 · Prostate Cancer, Insulin Resistance, Diabetes Mellitus, Type 2, Androgen Deficiency
What this study did
NCT05591235 · Nanjing First Hospital, Nanjing Medical University
2022-11 – 2023-02 · Type2diabetes, Insulin Resistance
What this study did
NCT03125694 · Tehran University of Medical Sciences
2015-02-01 – 2017-04-01 · Uncontrolled Type 2 Diabetes Mellitus
What this study did
NCT01095666 · AstraZeneca
2010-06 – 2013-03 · Type 2 Diabetes
What this study did
NCT01106690 · Janssen Research & Development, LLC
2010-06 – 2012-07 · Diabetes Mellitus, Type 2
What this study did
NCT01225081 · Astellas Pharma Inc
2010-09-15 – 2012-04-28 · Type 2 Diabetes Mellitus
What this study did
NCT01289119 · Takeda
2010-12 – 2011-12 · Diabetes Mellitus, Type 2
What this study did
NCT00763815 · Sanofi
2008-09 – 2011-06 · Diabetes Mellitus Type 2
What this study did
NCT00722371 · Merck Sharp & Dohme LLC
2008-09-05 – 2011-03-25 · Type 2 Diabetes Mellitus
What this study did
NCT00328393 · University of Erlangen-Nürnberg Medical School
2007-03 – 2011-01 · Hypertension, Diabetes Mellitus Type 2
What this study did
NCT00736099 · Boehringer Ingelheim
2008-08 – 2010-12 · Diabetes Mellitus, Type 2
What this study did
NCT00744367 · Hoffmann-La Roche
2008-10 – 2010-11 · Diabetes Mellitus Type 2
What this study did
NCT01156597 · University of Miami
2008-04 – 2010-09 · Type 2 Diabetes Mellitus
What this study did
NCT00970424 · Forest Laboratories
2009-08 – 2010-08 · Diabetes Mellitus, Type II
What this study did
NCT00220961 · The University of Texas Health Science Center at San Antonio
2004-01 – 2010-04 · Impaired Glucose Tolerance, Type 2 Diabetes
What this study did
NCT00432276 · Takeda
2007-01 – 2009-06 · Diabetes Mellitus
What this study did
NCT00641043 · Boehringer Ingelheim
2008-03 – 2009-06 · Diabetes Mellitus, Type 2
What this study did
NCT00770653 · Takeda
2007-04 – 2009-05 · Diabetes Mellitus, Dyslipidemias
What this study did
NCT01028391 · Merck Sharp & Dohme LLC
2007-09-01 – 2009-01-01 · Type 2 Diabetes Mellitus
What this study did
NCT00770952 · Takeda
2006-12 – 2008-12 · Diabetes Mellitus
What this study did
NCT00397631 · Merck Sharp & Dohme LLC
2006-12-19 – 2008-06-28 · Type 2 Diabetes Mellitus
What this study did
NCT00737347 · Northwestern University
2003-09 – 2008-04 · Type 2 Diabetes, Obesity
What this study did
NCT00372060 · Merck Sharp & Dohme LLC
2006-08-21 – 2008-02-05 · Type 2 Diabetes Mellitus
What this study did
NCT00772174 · Takeda
2007-01 – 2008-02 · Diabetes Mellitus
What this study did
NCT00286494 · Takeda
2006-02 – 2007-08 · Diabetes Mellitus
What this study did
NCT00376181 · Takeda
2006-06 – 2007-05 · Type 2 Diabetes
What this study did
NCT01124656 · Takeda
2006-09 – 2007-05 · Diabetes Mellitus, Type 2
What this study did
NCT00226330 · AstraZeneca
2005-03 – 2006-12 · Diabetes Mellitus, Type 2
What this study did
NCT00214565 · AstraZeneca
2004-08 – 2006-10 · Diabetes Mellitus, Type 2
What this study did
NCT00106808 · Bristol-Myers Squibb
2005-08 – 2006-08 · Type 2 Diabetes Mellitus
What this study did
NCT00138554 · Novartis
2004-11 – 2006-07 · Diabetes Mellitus, Type 2
What this study did
NCT00086502 · Merck Sharp & Dohme LLC
2004-06 – 2005-11 · Diabetes Mellitus, Type 2
What this study did
NCT00097279 · Novo Nordisk A/S
2004-08 – 2005-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00174993 · Takeda
2001-05 – 2005-01 · Diabetes Mellitus
What this study did
NCT00331487 · Takeda
2000-09 – 2004-03 · Diabetes Mellitus
What this study did
NCT00598793 · Novo Nordisk A/S
2002-11 – 2004-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00521820 · Takeda
2000-06 – 2003-10 · Diabetes Mellitus
What this study did
NCT00521742 · Takeda
2001-03 – 2003-01 · Diabetes Mellitus
What this study did
Other / comorbidity
NCT05946564 · Assistance Publique - Hôpitaux de Paris
2023-10-24 – 2028-11 · ANCA Associated Vasculitis, Rapidly Progressive Glomerulonephritis, Crescentic Glomerulonephritis
What this study did
NCT07056699 · The University of Texas Health Science Center at San Antonio
2026-07-01 – 2027-06-30 · Type1diabetes
What this study did
NCT05605158 · Tanta University
2022-11 – 2024-11 · Non Alcoholic Steatohepatitis
What this study did
NCT05521633 · King Edward Medical University
2019-06-06 – 2022-05-24 · NAFLD
What this study did
Phase 2/3 (8)
Type 2 Diabetes
NCT01318122 · Takeda
2008-05 – 2009-08 · Type 2 Diabetes Mellitus
What this study did
NCT01318070 · Takeda
2007-11 – 2008-10 · Type 2 Diabetes Mellitus
What this study did
NCT00482183 · Showa University
2003-07 – 2007-06 · Coronary Artery Disease, Type 2 Diabetes Mellitus
What this study did
NCT00143520 · Daiichi Sankyo
2004-12 – 2005-12 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT03452267 · Wayne State University
2019-09-01 – 2025-06 · Insulin Sensitivity
What this study did
NCT01184144 · University of Wisconsin, Madison
2010-08 – 2012-05 · Endometriosis
What this study did
NCT00153166 · Brigham and Women's Hospital
2004-01 – 2011-12 · Arterial Occlusive Disease, Intermittent Claudication, Insulin Resistance
What this study did
NCT01109030 · Tehran University of Medical Sciences
2010-04 – 2011-10 · Major Depressive Disorder
What this study did
Phase 2 (87)
Type 2 Diabetes
NCT04501406 · University of Florida
2020-12-15 – 2027-08-31 · Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Steatohepatitis
What this study did
NCT01935804 · King Abdulaziz University
2009-01 – 2014-01 · Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
What this study did
NCT00443755 · Mayo Clinic
2005-08 – 2010-08 · Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome
What this study did
NCT00770640 · Takeda
2008-08 – 2010-06 · Diabetes Mellitus
What this study did
NCT00722917 · Takeda
2008-07 – 2009-04 · Diabetes Mellitus
What this study did
NCT00771004 · Takeda
2006-08 – 2009-02 · Oxidative Stress, Coronary Artery Disease, Type 2 Diabetes
What this study did
NCT00500331 · GlaxoSmithKline
2007-01-23 – 2008-02-14 · Diabetes Mellitus, Type 2
What this study did
NCT00290940 · Daiichi Sankyo
2006-01 – 2007-04 · Diabetes Mellitus, Type 2
What this study did
NCT00196989 · GlaxoSmithKline
2005-09 – 2007-04 · Diabetes Mellitus, Type 2
What this study did
NCT00229684 · AstraZeneca
2004-09 – 2006-06 · Diabetes Mellitus, Type 2
What this study did
NCT00762736 · Takeda
2004-07 – 2005-10 · Diabetes Mellitus
What this study did
NCT00015626 · National Center for Research Resources (NCRR)
— · Insulin Resistance, Diabetes Mellitus
What this study did
NCT00676260 · Takeda
2002-12 – 2004-08 · Diabetes Mellitus
What this study did
NCT00280865 · AstraZeneca
2002-04 – 2003-06 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT02889003 · Versailles Hospital
2016-12 – 2028-12 · Chronic Myeloid Leukemia (CML)
What this study did
NCT05875675 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2023-07-01 – 2028-07-01 · Calcification of Aortic Valve, Aortic Valve Stenosis
What this study did
NCT06336798 · Emory University
2024-12-17 – 2028-02 · Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases
What this study did
NCT07117630 · Fudan University
2025-09-25 – 2027-12 · Breast Cancer
What this study did
NCT05727761 · University of Minnesota
2025-01-01 – 2027-07-30 · Oral Leukoplakia
What this study did
NCT06594172 · Affiliated Cancer Hospital & Institute of Guangzhou Medical University
2024-09-10 – 2027-06-30 · Radiation Disease, Cognitive Impairment, Drug Effect
What this study did
NCT06729996 · Mayo Clinic
2025-05-29 – 2027-05-31 · Pancreatitis, Chronic, Pancreatitis, Acute, Diabetes Mellitus
What this study did
NCT05013255 · West Virginia University
2021-12-23 – 2026-12 · Breast Cancer, Muscle Fatigue
What this study did
NCT05919147 · Pennington Biomedical Research Center
2024-01-03 – 2026-06-30 · Lung Cancer
What this study did
NCT05582707 · University of Maryland, Baltimore
2023-05-08 – 2025-12-25 · Intracerebral Haemorrhage, Intraventricular
What this study did
NCT04843046 · The University of Texas Health Science Center, Houston
2021-08-23 – 2025-10-15 · Cocaine Use Disorder
What this study did
NCT05394142 · Fundació Sant Joan de Déu
2022-05-24 – 2025-04 · Polycystic Ovary Syndrome (PCOS)
What this study did
NCT04794127 · Mario Negri Institute for Pharmacological Research
2022-02-02 – 2024-09-23 · Liposarcoma, Myxoid, Liposarcoma, Dedifferentiated, Liposarcoma, Round Cell
What this study did
NCT02852486 · University of Campinas, Brazil
2016-06-22 – 2024-02-07 · Leukemia, Chronic Myeloid
What this study did
NCT04419337 · Chang Gung Memorial Hospital
2019-09-15 – 2024-01-31 · Diabetes Mellitus, Stroke
What this study did
NCT04662866 · Oslo University Hospital
2021-02-10 – 2023-10 · Impaired Glucose Tolerance, Insulin Sensitivity, Glucose Metabolism Disorders
What this study did
NCT04995978 · St. Louis University
2021-12-01 – 2023-01-18 · Prostate Cancer, Insulin Resistance
What this study did
NCT04867252 · Khyber Medical University Peshawar
2021-05-03 – 2021-08-03 · PCOS
What this study did
NCT04883125 · Mansoura University
2018-01-01 – 2021-04-15 · Chronic Myelogenous Leukemia, BCR-ABL Positive, CML, Chronic Phase
What this study did
NCT02852083 · University Hospital Regensburg
2016-01 – 2020-07 · Squamous Cell Lung Cancer, Non-Squamous Cell Lung Cancer, Non-Small Cell Lung Cancer
What this study did
NCT01068444 · Kaohsiung Medical University Chung-Ho Memorial Hospital
2009-04 – 2020-07 · Hepatitis
What this study did
NCT02942758 · University Hospital Regensburg
2017-04-10 – 2020-03-25 · Acute Myeloid Leukemia
What this study did
NCT04113889 · Khyber Medical University Peshawar
2019-10-15 – 2020-01-30 · PCOS
What this study did
NCT03060772 · Emory University
2018-01-03 – 2020-01-28 · Alcoholism
What this study did
NCT02697617 · Indiana University
2016-01-26 – 2020-01 · Polycystic Kidney Disease
What this study did
NCT02917629 · National Cancer Institute (NCI)
2018-05-31 – 2019-08-28 · Oral Cavity Neoplasm, Oropharyngeal Neoplasm, Stage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7, Stage 0 Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage I Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
What this study did
NCT03864523 · Pujol, Aurora, M.D.
2016-01 – 2019-07 · Adrenomyeloneuropathy, X-linked Adrenoleukodystrophy
What this study did
NCT02347813 · University of Rochester
2014-11 – 2019-06-01 · Squamous Cell Carcinoma of the Skin
What this study did
NCT02730195 · Emory University
2016-05 – 2018-07 · Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
What this study did
NCT02585765 · James J. Peters Veterans Affairs Medical Center
2017-02-01 – 2018-04-01 · Spinal Cord Injury, Pressure Ulcers
What this study did
NCT01838317 · University of Texas Southwestern Medical Center
2013-05 – 2017-09-20 · Cancer of the Pancreas
What this study did
NCT00780234 · VA Office of Research and Development
2009-08 – 2017-08 · Lung Cancer, Endobronchial Dysplasia
What this study did
NCT02687425 · Meng Li
2016-02 – 2017-06 · Leukemia, Myelogenous, Chronic, BCR-ABL Positive
What this study did
NCT01655719 · University of Michigan
2012-04 – 2017-03-31 · Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene
What this study did
NCT02278562 · VA Office of Research and Development
2014-10-22 – 2017-03-01 · ESRD
What this study did
NCT02195791 · Taipei Medical University Shuang Ho Hospital
2014-07 – 2016-08 · Stroke
What this study did
Phase 1/2 (15)
Type 2 Diabetes
NCT01396564 · Coordinación de Investigación en Salud, Mexico
2005-10 – 2011-07 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT03109288 · National Institute of Allergy and Infectious Diseases (NIAID)
2017-08-11 – 2029-01-01 · Multiple Sclerosis
What this study did
NCT02767063 · Versailles Hospital
2016-07 – 2028-06 · Leukemia, Myeloid, Chronic-Phase
What this study did
NCT05107765 · The University of Texas Health Science Center, Houston
2022-05-12 – 2024-08-16 · Alcohol Use Disorder
What this study did
NCT04123067 · Milton S. Hershey Medical Center
2020-09-01 – 2021-04-07 · Stroke, Acute, Hyperglycemia, Diabetes
What this study did
NCT02338999 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2015-06-18 – 2020-07-14 · Systemic Lupus Erythematosus
What this study did
NCT03080480 · Children's Hospital of Fudan University
2017-09-01 – 2019-10-20 · Chronic Granulomatous Disease
What this study did
NCT03860753 · The University of Texas Health Science Center, Houston
2019-03-01 – 2019-08-23 · Alcohol Use Disorder
What this study did
NCT03757923 · Dow University of Health Sciences
2018-06-18 – 2019-01 · Menstrual Irregularities, Hyperandrogenism
What this study did
NCT01352182 · Children's Hospital Medical Center, Cincinnati
2011-10 – 2017-01 · Severe Sepsis, Septic Shock
What this study did
NCT01010243 · University of Regensburg
2009-10 – 2016-10 · Multiple Myeloma
What this study did
NCT01614301 · University of Regensburg
2012-05 – 2016-05 · Advanced Melanoma
What this study did
NCT02774343 · The University of Texas Health Science Center, Houston
2012-08 – 2015-06 · Cocaine Use Disorder, Alcohol Use Disorder
What this study did
NCT01395797 · New York State Psychiatric Institute
2011-03 – 2014-06 · Heroin Dependence, Nicotine Dependence
What this study did
NCT00919555 · Phoenix Neurological Associates, LTD
2008-06 – 2012-03 · Amyotrophic Lateral Sclerosis
What this study did
Phase 1 (62)
Type 2 Diabetes
NCT07053319 · The University of Texas Health Science Center at San Antonio
2026-05-11 – 2027-06-30 · Type 2 Diabetes
What this study did
NCT05760677 · Affiliated Hospital of Nantong University
2022-10-01 – 2024-09-30 · PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, T2D
What this study did
NCT02753803 · Dong-A ST Co., Ltd.
2016-07-27 – 2017-03-10 · Type 2 Diabetes
What this study did
NCT01082120 · AstraZeneca
2010-02 – 2010-05 · Type 2 Diabetes Mellitus
What this study did
NCT01088594 · Solvay Pharmaceuticals
2010-02 – 2010-03 · Type 2 Diabetes Mellitus
What this study did
NCT00511108 · Merck Sharp & Dohme LLC
2007-07-11 – 2009-02-24 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT00269061 · GlaxoSmithKline
started 2006-01 · Non-Insulin-Dependent Diabetes Mellitus
What this study did
NCT00232362 · Texas Tech University Health Sciences Center
2007-06 – 2008-06 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT05753657 · Rambam Health Care Campus
2022-12-25 – 2027-12-31 · Metastatic Breast Cancer, Hyperinsulinism, Hyperglycemia Drug Induced
What this study did
NCT02592317 · Aragon Pharmaceuticals, Inc.
2016-02-12 – 2027-12-31 · Prostatic Neoplasms, Castration-Resistant
What this study did
NCT06446531 · The University of Texas Health Science Center at San Antonio
2024-09-11 – 2027-07 · Pre-Diabetes, Weight, Body, Cardiovascular Diseases
What this study did
NCT03866408 · Mayo Clinic
2018-11-12 – 2026-12-31 · Obesity
What this study did
NCT07083401 · Boryung Pharmaceutical Co., Ltd
2025-07-05 – 2026-07-05 · Diabete Mellitus
What this study did
NCT07083388 · Boryung Pharmaceutical Co., Ltd
2025-07-03 – 2026-07-03 · Diabetes Mellitus
What this study did
NCT07444424 · AstraZeneca
2026-03-13 – 2026-07-02 · Healthy Participants
What this study did
NCT02133625 · Dana-Farber Cancer Institute
2011-08 – 2026-01 · Advanced Solid Tumor, Metastatic Solid Tumor
What this study did
NCT04300127 · Johns Hopkins University
2019-10-24 – 2025-03-18 · Gastroparesis
What this study did
NCT04658849 · St. Louis University
2020-12-02 – 2023-03-29 · Insulin Resistance, Prostate Cancer
What this study did
NCT02535832 · Ohio State University
2015-09 – 2022-10 · Rheumatoid Arthritis, Insulin Resistance
What this study did
NCT03566225 · Ain Shams University
2018-01-30 – 2021-03-30 · Pioglitazone
What this study did
NCT03440034 · Johns Hopkins University
2018-05-22 – 2020-12-31 · Myositis, Inclusion Body Myositis, Muscular Diseases, Musculoskeletal Disease, Neuromuscular Diseases, Nervous System Diseases
What this study did
NCT03231033 · Children's Hospital Medical Center, Cincinnati
2017-08-17 – 2019-04-02 · Autoimmune Pulmonary Alveolar Proteinosis
What this study did
NCT02919176 · Philip Kern
2016-09-01 – 2019-02-04 · Obese, Metabolic Syndrome
What this study did
NCT04671056 · Madrigal Pharmaceuticals, Inc.
2018-11-09 – 2019-01-05 · Healthy
What this study did
NCT02689843 · Shiraz University of Medical Sciences
2018-02-01 – 2018-12-30 · Polycystic Ovary Syndrome
What this study did
NCT03335956 · Corcept Therapeutics
2017-09-21 – 2018-06-25 · Healthy
What this study did
NCT03457597 · Corcept Therapeutics
2018-03-06 – 2018-04-28 · Healthy
What this study did
NCT02371603 · GlaxoSmithKline
2015-02-11 – 2015-08-12 · Anaemia
What this study did
NCT02341703 · Cairo University
2015-02 – 2015-07 · Polycystic Ovary Syndrome, Infertility
What this study did
NCT02342067 · Tobira Therapeutics, Inc.
2014-12 – 2015-04 · Healthy
What this study did
NCT01517165 · National Institute on Drug Abuse (NIDA)
2012-01-04 – 2015-02-02 · Opioid-Related Disorders
What this study did
NCT01817400 · University of Colorado, Denver
2013-03 – 2014-12 · Infertility, Female, Obesity
What this study did
NCT02222441 · Pfizer
2014-10 – 2014-12 · Healthy
What this study did
NCT01151670 · Wake Forest University Health Sciences
2010-08 – 2014-08 · Brain Neoplasms, Malignant, Brain Neoplasms, Benign, Malignant Meningioma, Glioblastoma Multiforme, Anaplastic Astrocytoma
What this study did
NCT01909141 · Cairo University
2013-08 – 2014-04 · Polycystic Ovary Syndrome, Infertility
What this study did
NCT01174056 · Washington University School of Medicine
2011-07 – 2014-03 · Lung Inflammation
What this study did
NCT01454336 · Royan Institute
2010-06 – 2013-07 · Liver Fibrosis
What this study did
NCT01431521 · Merck Sharp & Dohme LLC
2011-10-26 – 2012-10-01 · Non-alcoholic Fatty Liver Disease
What this study did
NCT00545857 · Stony Brook University
2002-06 – 2012-05 · Type 1 Diabetes Mellitus
What this study did
NCT01911728 · Astellas Pharma Europe B.V.
2011-07-25 – 2012-02-21 · Pharmacokinetics of MDV3100, Castration Resistant Prostate Cancer (CRPC)
What this study did
NCT00867126 · University of Texas Southwestern Medical Center
2009-03-02 – 2012-02 · Pancreatic Cancer
What this study did
NCT01489943 · GlaxoSmithKline
2011-09-19 – 2011-11-10 · Crohn's Disease
What this study did
NCT01309854 · AstraZeneca
2011-03 – 2011-05 · Rheumatoid Arthritis, Healthy Volunteers, Pharmacokinetics, Pioglitazone, Drug-drug Interaction, Amount of Pioglitazone in Blood
What this study did
NCT01276327 · Boehringer Ingelheim
2011-01 – 2011-05 · Healthy
What this study did
NCT01115712 · Merck Sharp & Dohme LLC
2010-05 – 2010-09 · Healthy, Overweight, Obesity
What this study did
NCT02172235 · Boehringer Ingelheim
2010-04 – 2010-07 · Healthy
What this study did
Phase 4 (119)
Type 2 Diabetes
NCT05838287 · The University of Texas Health Science Center at San Antonio
2023-07-10 – 2030-01 · Type 2 Diabetes Mellitus in Obese, Heart Failure With Preserved Ejection Fraction
What this study did
NCT06657209 · Stanford University
2025-01-13 – 2027-12-15 · Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes, Pre Diabetes
What this study did
NCT06989723 · Seoul National University Bundang Hospital
2025-01-01 – 2027-06-30 · Type 2 Diabetes, Fatty Liver
What this study did
NCT05305287 · The University of Texas Health Science Center at San Antonio
2022-11-01 – 2027-03-31 · Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
What this study did
NCT06851962 · Fundación para la Investigación del Hospital Clínico de Valencia
2025-05-26 – 2026-06-30 · Diabetes Mellitus Type 2
What this study did
NCT06875193 · Dong Wha Pharmaceutical Co. Ltd.
2024-05-28 – 2025-12-31 · Type2diabetes
What this study did
NCT05942963 · Jinnah Postgraduate Medical Centre
2023-10 – 2024-04 · Non-Alcoholic Fatty Liver Disease, Type2diabetes
What this study did
NCT04976283 · Getz Pharma
2021-09-15 – 2023-11-15 · Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis, NAFLD
What this study did
NCT05473806 · Seung Up Kim
2020-09-18 – 2023-02-19 · Hepatitis B, Chronic, Fibrosis, Liver, Diabetes Mellitus, Type 2
What this study did
NCT01107717 · The University of Texas Health Science Center at San Antonio
2009-01 – 2023-02-03 · Diabetes
What this study did
NCT04657939 · University of Leeds
2020-12-01 – 2022-10-31 · Diabetes Mellitus, Type 2
What this study did
NCT03646292 · Yonsei University
2018-12-06 – 2022-06-16 · MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes, Digestive System Disease, Liver Diseases, Fatty Liver, Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hypoglycemic Agents, Physiological Effects of Drugs, Sodium-Glucose Cotransporter 2 Inhibitors, Pioglitazone, Molecular Mechanisms of Pharmacological Action, Empagliflozin, Thiazolidinediones
What this study did
NCT04535700 · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
2020-09-18 – 2022-01-10 · Type 2 Diabetes
What this study did
NCT02315287 · Seoul National University Bundang Hospital
2014-09 – 2021-12-31 · Type 2 Diabetes
What this study did
NCT04470310 · Seoul National University Hospital
2015-12-31 – 2021-08-31 · Type 2 Diabetes Mellitus
What this study did
NCT04604223 · Dasman Diabetes Institute
2021-01-18 – 2021-06-29 · Covid19, Type 2 Diabetes
What this study did
NCT04392557 · University of Catanzaro
2020-07-01 – 2021-06-20 · Diabetes Mellitus, Type 2
What this study did
NCT04287387 · Peking Union Medical College Hospital
2020-03-02 – 2021-03-02 · Type2 Diabetes Mellitus
What this study did
NCT02653209 · Royal Devon and Exeter NHS Foundation Trust
2016-11-01 – 2021-01 · Type 2 Diabetes
What this study did
NCT03950505 · Yonsei University
2020-05-29 – 2020-12 · Non-alcoholic Steatohepatitis, Type2 Diabetes
What this study did
NCT03196362 · Sun Yat-sen University
2016-12-01 – 2018-12-31 · Type 2 Diabetes Mellitus
What this study did
NCT00700856 · Italian Society of Diabetology
2008-09 – 2018-12 · Type 2 Diabetes Mellitus, Cardiovascular Disease
What this study did
NCT01471808 · Sun Yat-sen University
2011-10 – 2018-12 · Diabetes Mellitus, Type 2
What this study did
NCT02142309 · University of Campania Luigi Vanvitelli
2005-10 – 2017-01 · Type 2 Diabetes
What this study did
NCT02365233 · The University of Texas Medical Branch, Galveston
2013-05-01 – 2016-12-31 · Type II Diabetes, Nonalcoholic Fatty Liver
What this study did
NCT01002547 · VA Office of Research and Development
2010-06-24 – 2016-12-31 · Nonalcoholic Steatohepatitis
What this study did
NCT01972724 · Takeda
2013-12-16 – 2016-10-17 · Type II Diabetes Mellitus
What this study did
NCT01895569 · University of Pavia
2013-06 – 2016-06 · Type 2 Diabetes Mellitus
What this study did
NCT02426294 · Pusan National University Hospital
2015-02 – 2016-05 · Type 2 Diabetes Mellitus
What this study did
NCT02072096 · Eli Lilly and Company
2014-02 – 2015-10 · Diabetes Mellitus, Type 2
What this study did
NCT01947790 · Xiang Guang-da
2013-09 – 2015-07 · LVM, Type 2 Diabetic Patients With IHD, Endothelial Function
What this study did
NCT00815399 · University of Campania Luigi Vanvitelli
2007-10 – 2015-04 · Type 2 Diabetes
What this study did
NCT03030300 · Qianfoshan Hospital
2008-01 – 2015-02 · Type2 Diabetes
What this study did
NCT00994682 · University of Florida
2008-12 – 2014-12 · Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
What this study did
NCT02099838 · Huazhong University of Science and Technology
2012-01 – 2013-12 · Diabetes Mellitus, Type 2
What this study did
NCT00399204 · Post Graduate Institute of Medical Education and Research, Chandigarh
2006-01 – 2012-12 · Type 2 Diabetes
What this study did
NCT01195090 · Sung-Chen Liu
2009-10 – 2012-04 · Type 2 Diabetes
What this study did
NCT00953498 · Centre Hospitalier Universitaire Dijon
2007-10 – 2012-03 · Type 2 Diabetes
What this study did
NCT01223196 · The University of Texas Health Science Center at San Antonio
2009-08 – 2011-12 · Type 2 Diabetes
What this study did
NCT01040819 · Baylor College of Medicine
2010-02 – 2011-12 · Type 2 Diabetes Mellitus
What this study did
NCT01588470 · The University of Texas Health Science Center at San Antonio
2006-06 – 2011-12 · Type 2 Diabetes, Coronary Heart Disease
What this study did
NCT00179400 · Albert Einstein College of Medicine
2000-12 – 2011-07 · Type 2 Diabetes Mellitus
What this study did
NCT00770835 · Takeda
2009-03 – 2011-05 · Diabetes Mellitus
What this study did
NCT00879970 · GlaxoSmithKline
2009-05 – 2010-11 · Diabetes Mellitus, Type 2
What this study did
NCT00656864 · University of Vermont
2008-05 – 2010-11 · Diabetes Mellitus, Type 2
What this study did
NCT00991055 · National Cheng-Kung University Hospital
2008-05 – 2010-10 · Type 2 Diabetes
What this study did
NCT00770445 · Takeda
2008-05 – 2010-07 · Diabetes Mellitus
What this study did
Early phase / not applicable (49)
Type 2 Diabetes
NCT02969798 · The University of Texas Health Science Center at San Antonio
2014-01-01 – 2027-07 · Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
What this study did
NCT02879409 · Weill Cornell Medical College in Qatar
2016-11 – 2026-10-01 · Diabetes Mellitus Type 2
What this study did
NCT01135394 · University of Maryland, Baltimore
2009-03 – 2018-05-31 · Type 2 Diabetes
What this study did
NCT02887625 · Dr. Muhammad Abdulghani
2015-02 – 2017-05 · Type 2 Diabetes
What this study did
NCT02236962 · Bayside Health
2012-04 – 2014-12 · Type 2 Diabetes, Obesity, Cardiovascular Disease
What this study did
NCT00855010 · University of Texas Southwestern Medical Center
2009-02 – 2013-12 · Obesity, Type 2 Diabetes
What this study did
NCT01963663 · Tehran University of Medical Sciences
2012-11 – 2013-04 · Type 2 Diabetes Mellitus
What this study did
NCT01147627 · Sun Yat-sen University
2010-08 – 2012-12 · Diabetes Mellitus, Type 2, Newly Diagnosed
What this study did
NCT00722631 · Kurume University
2007-05 – 2012-04 · Impaired Glucose Tolerance, Type 2 Diabetes Mellitus, Atherosclerosis
What this study did
NCT02027103 · Tehran University of Medical Sciences
2012-01 – 2012-04 · Type 2 Diabetes Mellitus
What this study did
NCT01570660 · German Diabetes Center
2002-02 – 2012-03 · Type 2 Diabetes Mellitus
What this study did
NCT01593371 · Tehran University of Medical Sciences
2011-07 – 2012-01 · Type 2 Diabetes Mellitus
What this study did
NCT00232583 · University of Texas Southwestern Medical Center
2003-11 – 2011-12 · Type 2 Diabetes Mellitus
What this study did
NCT00846716 · Shiga University
2008-03 – 2011-11 · Type 2 Diabetes Mellitus
What this study did
NCT00159211 · Assistance Publique - Hôpitaux de Paris
2005-05 – 2007-05 · Type 2 Diabetes
What this study did
NCT00364988 · Shanghai Jiao Tong University School of Medicine
2005-01 – 2006-01 · Type 2 Diabetes, Diabetic Nephropathy
What this study did
NCT00308373 · Mayo Clinic
2004-07 – 2005-11 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07604779 · Beni-Suef University
2026-05-17 – 2027-03-03 · Polycystic Ovarian Syndrome (PCOS)
What this study did
NCT07472179 · Mst.Sumyara Khatun
2024-08-12 – 2026-02-20 · PCOS(Insulin Resistant)
What this study did
NCT03864146 · VA Office of Research and Development
2019-07-17 – 2024-03-29 · Alcohol Use Disorder
What this study did
NCT00904046 · University of Texas Southwestern Medical Center
2010-01-15 – 2017-11-16 · Uric Acid Kidney Stone Disease
What this study did
NCT01748994 · Pennington Biomedical Research Center
2011-02 – 2016-12 · Obesity, Metabolic Syndrome
What this study did
NCT01301027 · University of Utah
2008-05 – 2015-12 · End Stage Renal Disease
What this study did
NCT02192684 · Stanford University
2010-09 – 2015-03 · Insulin Sensitivity, Obstructive Sleep Apnea
What this study did
NCT01289639 · VA Office of Research and Development
2005-10 – 2014-08 · Fatty Liver
What this study did
NCT01695707 · University of Rochester
2013-03 – 2014-06 · Atopic Dermatitis
What this study did
NCT00470262 · VA Office of Research and Development
2007-01 – 2014-06 · Metabolic Syndrome X, Prediabetic State
What this study did
NCT00763139 · Vanderbilt University
2009-04 – 2013-12 · Rheumatoid Arthritis
What this study did
NCT00745914 · The University of Hong Kong
2008-09 – 2013-12 · Endstage Renal Disease, Diabetes
What this study did
NCT01819402 · Kurume University
2012-03 – 2013-04 · To Evaluate the Effect of Pioglitazone on Glucose Metabolism of Fat Tissue by Using FDG-PET/CT Imaging
What this study did
NCT02305069 · University of Nottingham
2009-10 – 2012-09 · Obesity, Sarcopenia
What this study did
NCT01006018 · Emory University
2011-07 – 2011-12 · Prediabetic State
What this study did
NCT00868140 · Virginia Commonwealth University
2009-02 – 2011-08 · Polycystic Ovary Syndrome
What this study did
NCT00694759 · Oregon Health and Science University
2006-10 – 2011-07 · Polycystic Ovary Syndrome
What this study did
NCT00927355 · Emory University
2009-04 – 2011-07 · Osteoblast, Adipocytes, Bone Density, Osteocalcin, Adiponectin, Mesenchymal Stem Cells
What this study did
NCT00843791 · Oregon Health and Science University
2009-02 – 2011-05 · Obesity, Insulin Resistance
What this study did
NCT00926016 · Brooke Army Medical Center
2006-06 – 2010-09 · Chronic Hepatitis C
What this study did
NCT01133561 · Cairo University
2010-01 – 2010-08 · Psoriasis
What this study did
NCT00656851 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2005-09 – 2010-08 · HIV Infections, Cardiovascular Disease, Insulin Resistance, HIV Lipodystrophy, The Metabolic Syndrome
What this study did
NCT01023620 · University of Texas Southwestern Medical Center
2009-10 – 2010-05-31 · HIV Infections
What this study did
NCT00586261 · Mayo Clinic
2006-03 – 2009-07 · Chronic Kidney Disease
What this study did
NCT00531882 · University Hospitals Cleveland Medical Center
2007-09 – 2009-02 · Cystic Fibrosis
What this study did
NCT00681733 · Govind Ballabh Pant Hospital
2007-01 – 2008-12 · Metabolic Parameters and Liver Histology
What this study did
NCT01258322 · Huashan Hospital
2008-01 – 2008-09 · Peritoneal Dialysis, Pioglitazone, Hypertriglyceridemia, Insulin Resistance, Inflammation
What this study did
NCT00598013 · Yonsei University
2004-11 – 2007-11 · Kidney Transplantation, Insulin Resistance, Atherosclerosis
What this study did
NCT00322868 · University Hospitals Cleveland Medical Center
2006-04 – 2007-04 · Cystic Fibrosis
What this study did
NCT00151710 · Radboud University Medical Center
— · Congenital Adrenal Hyperplasia
What this study did
NCT00154037 · Technische Universität Dresden
2005-10 – 2006-09 · Healthy Subjects
What this study did
NCT00459940 · University of Aarhus
2004-09 – 2006-03 · Growth Hormone Deficiency
What this study did
Used as active comparator (54)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (18)
Type 2 Diabetes
NCT05028140 · EMS
2024-10-08 – 2027-09 · Type II Diabetes
What this study did
NCT00839527 · GlaxoSmithKline
2009-02 – 2013-04 · Diabetes Mellitus, Type 2
What this study did
NCT01106131 · Chong Kun Dang Pharmaceutical
2010-05 – 2012-11 · Type 2 Diabetes Mellitus
What this study did
NCT01076075 · Merck Sharp & Dohme LLC
2010-06-03 – 2012-01-19 · Type 2 Diabetes Mellitus
What this study did
NCT01026194 · Tanabe Pharma Corporation
2009-12 – 2011-06 · Type 2 Diabetes Mellitus
What this study did
NCT00909597 · Hoffmann-La Roche
2009-05 – 2010-11 · Diabetes Mellitus Type 2
What this study did
NCT00541450 · Merck Sharp & Dohme LLC
2008-01-15 – 2010-01-16 · Type 2 Diabetes Mellitus
What this study did
NCT00655863 · Takeda
2007-07 – 2009-12 · Diabetes Mellitus
What this study did
NCT00532935 · Merck Sharp & Dohme LLC
2008-01-26 – 2009-10-23 · Type 2 Diabetes Mellitus
What this study did
NCT00484198 · Daiichi Sankyo
2007-04-23 – 2009-02-12 · Type 2 Diabetes Mellitus
What this study did
NCT00727857 · Takeda
2007-06 – 2008-08 · Diabetes Mellitus
What this study did
NCT00571519 · Daiichi Sankyo
2007-11-14 – 2008-05-23 · Type 2 Diabetes Mellitus
What this study did
NCT00328627 · Takeda
2006-05 – 2008-03 · Type 2 Diabetes Mellitus
What this study did
NCT00395512 · Takeda
2006-11 – 2008-02 · Diabetes Mellitus
What this study did
NCT00106704 · Merck Sharp & Dohme LLC
2005-03 – 2007-01 · Diabetes Mellitus, Type 2
What this study did
NCT00094757 · Merck Sharp & Dohme LLC
2004-10-06 – 2006-04-28 · Diabetes Mellitus, Type 2
What this study did
Phase 2/3 (1)
Type 2 Diabetes
NCT00353587 · Gilead Sciences
2006-05 – 2007-11 · Type 2 Diabetes
What this study did
Phase 2 (16)
Type 2 Diabetes
NCT02303405 · Charles Drew University of Medicine and Science
2014-11 – 2017-11 · Diabetes Mellitus Type 2 With Hyperglycemia
What this study did
NCT01217073 · Merck Sharp & Dohme LLC
2010-10-08 – 2013-04-01 · Type 2 Diabetes Mellitus
What this study did
NCT01043029 · Hoffmann-La Roche
2010-05 – 2012-07 · Diabetes Mellitus Type 2
What this study did
NCT01103414 · Metabolic Solutions Development Company
2010-09 – 2011-12 · Type 2 Diabetes
What this study did
NCT01230749 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2010-12 – 2011-06 · Diabetes Mellitus, Type 2
What this study did
NCT01280695 · Metabolic Solutions Development Company
2011-02 – 2011-06 · Diabetes Mellitus, Type 2
What this study did
NCT01028963 · Amgen
2010-01 – 2010-11 · Type 2 Diabetes Mellitus
What this study did
NCT00814372 · Gilead Sciences
2008-12 – 2010-02 · Type 2 Diabetes Mellitus
What this study did
NCT00631007 · InteKrin Therapeutics, Inc.
2008-02 – 2009-09 · Type 2 Diabetes Mellitus
What this study did
NCT00760578 · Metabolic Solutions Development Company
2008-09 – 2009-02 · Type 2 Diabetes Mellitus
What this study did
NCT00575874 · Daiichi Sankyo Co., Ltd.
2007-08 – 2009-01 · Type 2 Diabetes
What this study did
NCT00461006 · Hoffmann-La Roche
2007-06 – 2008-09 · Diabetes Mellitus Type 2
What this study did
NCT00388518 · Hoffmann-La Roche
2006-11 – 2008-03 · Diabetes Mellitus Type 2
What this study did
NCT00461058 · Hoffmann-La Roche
2007-05 – 2007-12 · Diabetes Mellitus Type 2
What this study did
NCT00543959 · Merck Sharp & Dohme LLC
2006-06 – 2007-08 · Diabetes Mellitus Type 2
What this study did
Other / comorbidity
NCT05254626 · Cairo University
2022-08-01 – 2024-07-23 · Non-alcoholic Steatohepatitis
What this study did
Phase 1 (5)
Other / comorbidity
NCT03298464 · NGM Biopharmaceuticals, Inc
2017-09-11 – 2018-07-17 · Obese
What this study did
NCT03117517 · Khyber Medical University Peshawar
2017-03-20 – 2018-03-07 · Polycystic Ovarian Syndrome
What this study did
NCT00649012 · Mylan Pharmaceuticals Inc
2003-03 – 2003-03 · Healthy
What this study did
NCT00649558 · Mylan Pharmaceuticals Inc
2003-02 – 2003-03 · Healthy
What this study did
Phase 4 (12)
Type 2 Diabetes
NCT06399835 · Seoul National University Bundang Hospital
2024-02-01 – 2027-12-31 · Type 2 Diabetes
What this study did
NCT03910361 · Dong-A ST Co., Ltd.
2019-04-12 – 2020-07-02 · Type2 Diabetes, Non-Alcoholic Fatty Liver Disease
What this study did
NCT02763007 · Kun-Ho Yoon
2016-05-18 – 2019-02-28 · Diabetes Mellitus, Type 2
What this study did
NCT02231021 · Kun-Ho Yoon
2014-09 – 2019-01-28 · Type 2 Diabetes Mellitus
What this study did
NCT02694263 · University of Leicester
2016-07 – 2018-09-13 · Diabetes Mellitus, Type 2
What this study did
NCT02875821 · Yonsei University
2016-04-26 – 2017-06-07 · Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)
What this study did
NCT01882907 · Pusan National University Hospital
2009-12 – 2013-03 · Type 2 Diabetes
What this study did
NCT02292290 · University of Leicester
2011-04 – 2012-12 · Type 2 Diabetes
What this study did
NCT00845182 · The University of Texas Health Science Center at San Antonio
2007-06 – 2010-07 · Type 2 Diabetes, Healthy, Impaired Glucose Tolerance
What this study did
NCT00780715 · University of Dundee
2008-12 – 2009-10 · Diabetes Mellitus, Type 2
What this study did
NCT00571506 · University of Arkansas
2004-05 – 2007-08 · Diabetes Mellitus, Type 2, Vascular Diseases
What this study did
Other / comorbidity
NCT01339143 · Korea University Anam Hospital
2010-04 – 2013-05 · Diabetes Mellitus, Oxidative Stress
What this study did
Early phase / not applicable (2)
Type 2 Diabetes
NCT05501483 · Karolinska Institutet
2023-02-08 – 2032-12-31 · Type 2 Diabetes
What this study did
NCT05422092 · First Affiliated Hospital Xi'an Jiaotong University
2022-09-20 – 2023-12 · Type 2 Diabetes Mellitus With Complication
What this study did
Appears in other studies (13)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (11)
Type 2 Diabetes
NCT00789750 · Daiichi Sankyo
2009-04 – 2012-07 · Type 2 Diabetes Mellitus
What this study did
NCT01064687 · Eli Lilly and Company
2010-02 – 2012-05 · Diabetes Mellitus, Type 2
What this study did
NCT00885352 · Merck Sharp & Dohme LLC
2009-04-15 – 2010-11-10 · Type 2 Diabetes Mellitus
What this study did
NCT00683878 · AstraZeneca
2008-07 – 2010-06 · Type 2 Diabetes
What this study did
NCT00680745 · AstraZeneca
2008-04 – 2010-05 · Type 2 Diabetes
What this study did
NCT00121667 · AstraZeneca
2005-08 – 2010-02 · Diabetes Mellitus, Type 2
What this study did
NCT00295633 · AstraZeneca
2006-03 – 2008-10 · Diabetes Mellitus, Type 2
What this study did
NCT00411892 · Novo Nordisk A/S
2006-11-29 – 2008-03-18 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00099853 · Novartis Pharmaceuticals
2004-05 – 2008-01 · Diabetes Mellitus, Type 2
What this study did
NCT00086515 · Merck Sharp & Dohme LLC
2004-06-30 – 2007-02-02 · Diabetes Mellitus, Type II
What this study did
Phase 2 (1)
Other / comorbidity
NCT00362440 · Beth Israel Deaconess Medical Center
2006-08 – 2011-06 · HIV Lipodystrophy
What this study did
Early phase / not applicable (1)
Type 2 Diabetes
NCT00639457 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2005-01 – 2009-12 · HIV Infections, Type 2 Diabetes, Obesity, HIV, AIDS, Cardiovascular Disease, Lipodystrophy
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Type 2 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pioglitazone (Actos): this drugApprovedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
Acarbose (Precose / Glucobay)
ApprovedUS marketing discontinued
Small moleculeAlpha-glucosidasenot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01451398: Change in HbA1c from baseline to week 24: Technosphere Insulin + oral agents -0.82% (n=177) vs Technosphere powder (placebo) -0.42% (n=176); difference -0.40% (95% CI -0.57 to -0.23), p<0.0001 (CT.gov posted results).
Alogliptin (Nesina)ApprovedSmall moleculeDPP-4Partial signal
NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed
NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8%
Bexagliflozin (Brenzavvy)ApprovedSmall moleculeSGLT2Reliable signal
NCT02769481: Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058)
NCT03259789: Change From Baseline in HbA1c at Week 24 for Double-blind Group (Baseline to week 24): Double-blind Group: Bexagliflozin 20 mg -1.09 percentage of HbA1c (Standard Error 0.076) vs Double-blind Group: Placebo -0.56 percentage of HbA1c (Standard Error 0.075)
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Partial signal
NCT03170518: Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002).
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Colesevelam (Welchol)ApprovedSmall moleculeBile acid sequestrantnot yet gradedNo reviewed efficacy summary in this indication
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Partial signal
NCT01392677: Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02)
NCT00984867: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin -0.45 Percent (95% CI -0.55 to -0.35) vs Placebo 0.04 Percent (95% CI -0.06 to 0.14)
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT03495102: Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04)
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT01131676: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1%
NCT03429543: HbA1c change at week 26, empagliflozin pooled (10 mg and 25 mg) vs placebo: adjusted mean difference -0.84% (95% CI -1.50 to -0.19), p=0.0116. Treatment failure by week 26 in the small monotherapy cohort: 50.0% vs 60.0%, Fisher p=1.0 (CT.gov posted results).
Ertugliflozin (Steglatro)ApprovedSmall moleculeSGLT2Reliable signal
NCT01986881: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years
NCT01958671: Change in A1C at Week 26 versus placebo: ertugliflozin 5 mg −0.99 percentage points (95% CI −1.22 to −0.76; p<0.001); ertugliflozin 15 mg −1.16 percentage points (95% CI −1.39 to −0.93; p<0.001).
Glimepiride (Amaryl)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glipizide (Glucotrol)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glyburide (DiaBeta)ApprovedSmall moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT00982644: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97)
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)Partial signal
NCT00856986: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07)
NCT00283751: HbA1c at 52 weeks: decreased from 8.6% to 7.2% with insulin detemir vs 8.6% to 7.1% with insulin glargine (no significant difference between arms); non-inferiority of detemir to glargine demonstrated.
Insulin Efsitora Alfa (Onswik)ApprovedProtein / enzyme therapeuticInsulin receptor (basal)Partial signal
NCT05662332: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545)
NCT05275400: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] (Baseline, Week 26): 500 U/mL - Insulin Efsitora -0.81 Percentage of HbA1c (Standard Error 0.0302) vs 100 U/mL - Insulin Degludec -0.72 Percentage of HbA1c (Standard Error 0.0424)
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)Partial signalNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT03338010: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062)
NCT02302716: Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks): LY2963016 -1.25 Percentage of glycosylated hemoglobin (Standard Error 0.066) vs LANTUS® -1.22 Percentage of glycosylated hemoglobin (Standard Error 0.067)
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT01499082: Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061)
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptorPartial signal
NCT00135057: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly.
Insulin Icodec (Awiqli)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT06340854: Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89)
NCT04760626: Change in Glycated Haemoglobin (HbA1c) (Baseline (week 0), week 52): Insulin Icodec -1.68 Percentage of HbA1c (Standard Error 0.09) vs Once Daily Basal Insulin Analogue -1.31 Percentage of HbA1c (Standard Error 0.12)
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptorReliable signalFeatured results are non-efficacy only in this race
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptorPartial signal
NCT03952143: Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061)
NCT03214380: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 (Baseline, Week 26): LY900014 -0.38 percentage of HbA1c (Standard Error 0.042) vs Insulin Lispro (Humalog) -0.43 percentage of HbA1c (Standard Error 0.042)
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Linagliptin (Tradjenta)ApprovedSmall moleculeDPP-4Partial signal
NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years
NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptorReliable signal
NCT00318461: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07)
NCT00318422: HbA1c change from baseline at 26 weeks (added to glimepiride): liraglutide 1.2/1.8mg -1.1% (baseline 8.5%) vs placebo +0.2% (baseline 8.4%, P<0.0001) vs rosiglitazone -0.4% (baseline 8.4%, P<0.0001)
Lixisenatide (Adlyxin / Lyxumia)ApprovedPeptideGLP-1 receptorPartial signal
NCT00707031: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054)
NCT00688701: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 (Baseline, Week 12): Lixisenatide (Two-Step Titration) -0.73 percentage of hemoglobin (Standard Error 0.116) | Lixisenatide (One-Step Titration) -0.85 percentage of hemoglobin (Standard Error 0.119)
Metformin (Glucophage)
ApprovedUS marketing discontinued
Small moleculeAMPKReliable signal
NCT00004992: Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%)
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
SAR341402ApprovedPeptideInsulin receptorPartial signal
NCT03211858: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041)
Saxagliptin (Onglyza)
ApprovedUS marketing discontinued
Small moleculeDPP-4Reliable signal
NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07)
NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1)
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Sitagliptin (Januvia)ApprovedSmall moleculeDPP-4Partial signal
NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03)
NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3)
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)Partial signal
NCT04255433: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579
NCT05260021: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (Baseline, Week 30): Pooled Doses of Tirzepatide (5 mg, 10 mg) -2.03 percentage of HbA1c (Standard Error 0.165) | Placebo -0.23 percentage of HbA1c (Standard Error 0.229)
Miglitol (Glyset)US approval withdrawnSmall moleculeAlpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
Repaglinide (Prandin / NovoNorm)US approval withdrawnSmall moleculeSUR1 (short-acting)Partial signalNo reviewed efficacy summary in this indication
AlbenatidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
AleniglipronPhase 3Small moleculeGLP-1 receptorWeak signal
NCT05762471: Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo
Anagliptin (Suiny)Phase 3Small moleculeDPP-4Partial signal
NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo.
NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established.
ASC30Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 3Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Reliable signal
NCT06350890: SYMPHONY 1 (NCT06350890, n=408): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.3%, statistically superior to placebo
NCT06353347: SYMPHONY 2 (NCT06353347, n=551): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.2%, statistically superior to placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06897202: Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
BofanglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT06534411: Primary endpoints: CagriSema 1.0 mg/1.0 mg superior to tirzepatide 5 mg for weight loss at week 60 (12.4% vs 9.1%) and non-inferior for HbA1c reduction (1.71% vs 1.67%) (2026-09-21).
Chiglitazar (Bilessglu)Phase 3Small moleculePPAR (pan-agonist)Reliable signal
NCT04807348: RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008.
NCT02173457: CMAS trial, primary endpoint HbA1c change from baseline at week 24: chiglitazar 32mg and 48mg both non-inferior to sitagliptin 100mg, with treatment differences of -0.04% (95% CI -0.22 to 0.15) and -0.08% (95% CI -0.27 to 0.10) vs sitagliptin (arm sizes n=245/246/248, total 739, matching this trial's design and enrollment of 740)
CofrogliptinPhase 3Small moleculeDPP-4Reliable signal
NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin
NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001
Dapagliflozin / Linagliptin (Dapalina)Phase 3Small moleculeSGLT2;DPP-4Partial signal
NCT06329674: Change in HbA1c at Week 24: -0.77% AJU-A51 vs +0.10% linagliptin+placebo; LS mean difference -0.88% (95% CI -1.07, -0.68), p<0.0001
Dorzagliatin (Huatangning)Phase 3Small moleculeGlucokinasePartial signal
NCT04531631: Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). missed
EcnoglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06235086: Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30).
EfpeglenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT03353350: Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care).
Efsubaglutide AlfaPhase 3Protein / enzyme therapeuticGLP-1 receptorReliable signal
NCT04994288: HbA1c change from baseline at week 24 (SUPER-1, phase III stage): 1 mg dose -1.73% (95% CI -20.98,-16.83 mmol/mol), 3 mg dose -2.15% (95% CI -25.68,-21.31 mmol/mol); estimated treatment difference vs placebo -1.26% (1 mg, 95% CI -17.39,-10.06 mmol/mol) and -1.68% (3 mg, 95% CI -22.08,-14.64 mmol/mol), both CIs excluding zero.
NCT04998032: HbA1c change from baseline at week 24 (SUPER-2, add-on to metformin): Efsubaglutide 3 mg -1.80% vs placebo -0.74%; estimated treatment difference -1.06% (p<0.001)
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signal
NCT06579105: HbA1c reduction over 26 weeks: 1.9% with elecoglipron 75 mg (highest dose) vs 0.2% with placebo
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2Reliable signal
NCT04634500: Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35%
NCT04632862: Placebo-adjusted mean change in HbA1c from baseline at week 24 in the enavogliflozin 0.3 mg group: -0.99% (95% confidence interval -1.24%, -0.74%).
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Lobeglitazone (Duvie)Phase 3Small moleculePPAR-gammaWeak signal
NCT03739125: HbA1c change at 24 weeks vs placebo (Study 1, empagliflozin 10 mg plus metformin background): -0.71% (95% CI -0.88 to -0.55), p<0.001. The publication reports Study 2 (empagliflozin 25 mg background, NCT03627182) separately.
NCT01106131: HbA1c change at week 24: -0.74% lobeglitazone vs -0.74% pioglitazone (difference 0.01%, 95% CI -0.16 to 0.18); noninferior.
Pioglitazone (JT-001)Phase 3Small moleculePPAR-gammaReliable signal
NCT05101135: JT-001 (pioglitazone 15mg) add-on vs placebo, week 24 HbA1c change: -0.47% (95% CI -0.61 to -0.33), P<0.0001. HbA1c<7% achieved: 56.8% vs 28%; HbA1c<6.5%: 23.2% vs 9.6% (P<0.0001 for all).
Rosiglitazone (Avandia)DiscontinuedSmall moleculePPAR-gammaPartial signal
NCT00081328: Loss of glycemic control over an average 3.86 years: metformin plus rosiglitazone 38.6% (90/233) vs metformin alone 51.7% (120/232), P=0.006; metformin plus lifestyle 46.6% (109/234), not significantly different from either (TODAY, NEJM 2012).
NCT00279045: Cumulative incidence of monotherapy failure at 5 years: rosiglitazone 15%, metformin 21%, glyburide 34%; rosiglitazone reduced the risk of monotherapy failure by 32% vs metformin and 63% vs glyburide (P<0.001 for both comparisons).

Large race: only the 63 furthest-along competitors are listed; 87 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(23 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Actos (Pioglitazone) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (5)
December 2026 (5)
Phase 2Breast Cancer, Muscle FatigueRecruiting
Est. primary completion 2026-12 · NCT05013255 · CT.gov ↗
What to watch
Early phase / not applicablePolycystic Ovarian Syndrome (PCOS)Active not recruiting
Est. primary completion 2026-12-03 · NCT07604779 · CT.gov ↗
What to watch
Phase 1ObesityRecruiting
Est. primary completion 2026-12-30 · NCT03866408 · CT.gov ↗
What to watch
Phase 1Metastatic Breast Cancer, Hyperinsulinism, Hyperglycemia Drug InducedRecruiting
Est. primary completion 2026-12-31 · NCT05753657 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2026-12-31 · NCT06989723 · CT.gov ↗
What to watch
2027 (14)
January 2027 (1)
Phase 1/2Multiple SclerosisRecruiting
Est. primary completion 2027-01-01 · NCT03109288 · CT.gov ↗
What to watch
February 2027 (1)
Early phase / not applicableType 2 DiabetesRecruiting
Est. primary completion 2027-02-28 · NCT02969798 · CT.gov ↗
What to watch
March 2027 (1)
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-03-31 · NCT05305287 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Pancreatitis, Chronic, Pancreatitis, Acute, Diabetes MellitusRecruiting
Est. primary completion 2027-05-31 · NCT06729996 · CT.gov ↗
What to watch
June 2027 (3)
Phase 2Breast CancerRecruiting
Est. primary completion 2027-06 · NCT07117630 · CT.gov ↗
What to watch
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2027-06-01 · NCT07053319 · CT.gov ↗
What to watch
Phase 3Type1diabetesRecruiting
Est. primary completion 2027-06-01 · NCT07056699 · CT.gov ↗
What to watch
July 2027 (2)
Phase 1Pre-Diabetes, Weight, Body, Cardiovascular DiseasesRecruiting
Est. primary completion 2027-07 · NCT06446531 · CT.gov ↗
What to watch
Phase 2Oral LeukoplakiaRecruiting
Est. primary completion 2027-07-30 · NCT05727761 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Type 2 DiabetesRecruiting
Est. primary completion 2027-08-31 · NCT04501406 · CT.gov ↗
What to watch
November 2027 (1)
Phase 4MASH - Metabolic Dysfunction-Associated SteatohepatitisRecruiting
Est. primary completion 2027-11 · NCT07848191 · CT.gov ↗
What to watch
December 2027 (3)
Phase 1/2Leukemia, Myeloid, Chronic-PhaseActive not recruiting
Est. primary completion 2027-12 · NCT02767063 · CT.gov ↗
What to watch
Phase 2Chronic Myeloid Leukemia (CML)Recruiting
Est. primary completion 2027-12 · NCT02889003 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-12-15 · NCT06657209 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
Phase 2Pulmonary Hypertension, Pulmonary Hypertension Due to Lung DiseasesRecruiting
Est. primary completion 2028-02 · NCT06336798 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3ANCA Associated Vasculitis, Rapidly Progressive Glomerulonephritis, Crescentic GlomerulonephritisRecruiting
Est. primary completion 2028-04-24 · NCT05946564 · CT.gov ↗
What to watch
2029 (2)
April 2029 (1)
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2029-04-30 · NCT06246799 · CT.gov ↗
What to watch
August 2029 (1)
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2029-08 · NCT05838287 · CT.gov ↗
What to watch

See the full readout calendar ↗